S6 Ep9: Building a resilient vaccine supply chain

Episode Summary

Executive Summary: The episode examines how COVID-19 exposed major market failures in vaccine R&D, manufacturing, and distribution, and argues that governments need better “push” and “pull” incentives to speed production in future pandemics. Chad Baume finds the U.S. most effective on manufacturing but poor on sharing, Europe better on sharing but slower to secure doses, India late to subsidize and then restrictive on exports, and sees the WTO as a potential coordinator for cross-border vaccine supply chains.

Main Topics: Why vaccines need government intervention (Priority: 5/5): Baume explains that vaccines face demand-side failures (people undervalue public benefits) and supply-side failures (firms won’t invest heavily in risky R&D when they may only be paid to produce, not discover, a vaccine). Pandemic-scale urgency and scarcity (Priority: 5/5): COVID created an unprecedented need for billions of doses at the same time, plus extreme time pressure because lives and economic activity were being lost, making vaccine production much harder than routine immunization. Push and pull incentives (Priority: 5/5): The discussion distinguishes push policies (R&D subsidies, funding phase 3 trials, pre-building capacity) from pull policies (bonuses or contracts tied to early delivery dates) as ways to de-risk innovation and accelerate output. Fragmented global supply chains (Priority: 4/5): Vaccine production depended on international inputs, outsourced manufacturing, and specialized suppliers, creating shortages and coordination problems when many governments demanded the same inputs simultaneously. Comparative policy performance across regions (Priority: 5/5): Baume assesses the U.S., EU, UK, and India: the U.S. excelled at diversification and early manufacturing support but hoarded doses; Europe shared more but secured doses later; the UK bet early but on a smaller portfolio; India acted late and imposed export restrictions. Role of the WTO in future pandemics (Priority: 4/5): The episode argues the WTO could coordinate subsidies, supply chains, and cross-border commerce in a future health emergency, though it was largely absent during COVID due to lack of member demand, limited fit with its usual subsidy role, and leadership transition.

Key Arguments: Vaccines have a demand-side market failure because individual consumers do not fully value the social benefits of immunization, so governments must become the buyers and distributors. There is a supply-side hold-up problem: firms face huge upfront R&D and clinical-trial costs but may only be paid to manufacture after success, discouraging early investment. The pandemic worsened the failure because demand became global and simultaneous, and the cost of delay was measured in deaths and economic shutdowns. Push subsidies can fund R&D and also finance manufacturing capacity before trials finish, so production can start immediately if a vaccine succeeds. Pull incentives matter because contracts that reward early delivery can motivate speed, not just eventual supply. Writing a contract for early delivery is different from buying a fixed quantity, because early access without added capacity can simply move one country ahead in the queue and harm others. The U.S. approach worked best on manufacturing because it diversified bets across several candidates, subsidized early, and funded capacity before trial results were known. The U.S. policy was weak on sharing, while Europe performed better on export-sharing but worse on speed to early doses due to less aggressive advance commitments. India’s vaccine industry was important globally, but government support came too late and export restrictions undermined COVAX and global distribution. The WTO is a logical forum for pandemic supply-chain coordination because these are cross-border trade and subsidy issues, even though it did not play that role during COVID.

Data Points: Vaccine candidates subsidized by the U.S.: 6 or 7 - Baume says the U.S. subsidized a small set of candidates out of hundreds to diversify its bets. Vaccine candidates in development globally: Hundreds - The WHO tracked hundreds of vaccine candidates in clinical trials during the pandemic. Likely successful vaccines from initial candidates: 4, 5, 6, or 7 - Only a handful of candidates ultimately passed clinical trials and were deployed widely. Routine annual newborn vaccination demand: A couple hundred million doses - Used as a contrast to pandemic-scale demand, which was far larger and immediate. Pandemic vaccine demand scale: About 8 billion people / 16 billion doses - Baume describes the demand shock as essentially global and simultaneous. Phase 3 trial size: 30,000 to 60,000 people - He explains the scale of late-stage clinical testing needed before approval. Phase 3 trial duration: 4, 5, or 6 months - Typical time needed to run the final trial phase once underway. Moderna pull incentive bonus: $3 per dose - A public contract example suggesting payment for early delivery by a deadline. Public procurement timing: Early 2020 to December 2020 - The U.S. funded capacity so that production was ready when authorization arrived in December 2020.

Pivotal Quotes: "There wasn't anything off the shelf at that moment in time, despite their best efforts." — Chad Baume: On the lack of a ready-made policy playbook for pandemic vaccine manufacturing. "The two key elements, what made the pandemic really different for vaccines is immense scale, the number of doses you needed, and how quickly you wanted to have them delivered." — Chad Baume: Summarizing why COVID vaccine production was an unprecedented policy challenge. "If you get doses delivered by this early date, get an extra bonus payment kind of thing." — Chad Baume: Explaining how pull contracts create incentives for speed.

Implications: Future pandemic preparedness should combine early R&D subsidies, pre-approved manufacturing capacity, and international coordination on inputs and exports. Without better cooperation, countries will repeat zero-sum competition, delays, and inequitable access.